Security key
83086J200
Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE)
CUSIP: 83086J200
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, par value $0.001
- Total 13F shares
- 2,009,303
- Total 13F value
- $31,404,827
- Share change
- +2,007,703
- SEC-reported price per share
- $15.64
- Number of holders
- 3
- Value change
- +$31,400,475
- Number of buys
- 2
- Shares outstanding
- 37,329,162
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
3
Top holders
3
SKYE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Skye Bioscience, Inc. SEC filings
Skye Bioscience, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 83086J200
Recent filing periods:
Ownership snapshot
Top reported holders of SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Versant Ventures III, LLC
Disclosed value leader
Versant Ventures III, LLC
Comparable rows
0/8
Latest evidence
29 Feb 2024
3/4/5
13F
Highest disclosed value: $9,386,012
8 rows are not safely comparable across share classes.
Showing 1-6 of 8 holder rows.
Quick read
Versant Ventures III, LLC has the largest disclosed position value at $9.39M.
0 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Versant Ventures III, LLC's linked filing trail.
Disclosed position value
Top 3
Versant Ventures III, LLC
$9.39M
Emerald Health Sciences Inc.
$3.17M
Financial Gravity Asset Managemen...
$4.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Versant Ventures III, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$9,386,012
501,925,802 shares
|
— | 18 Aug 2023 |
| Emerald Health Sciences Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$3,167,928
169,407,901 shares
|
— | 10 Nov 2022 |
| Financial Gravity Asset Management, Inc. |
13F
Company
|
—
denominator unverified
|
$4,352
1,600 shares
|
— | 31 Dec 2023 |
| James L. Heppell |
3/4/5
Director
|
—
denominator unverified
|
—
1,350,000 shares
|
— | 14 Sep 2021 |
| Sukhwinder Singh Rai |
3/4/5
Director
|
—
denominator unverified
|
—
250,000 shares
|
— | 05 Jan 2023 |
| Keith Wayne Ward |
3/4/5
Director
|
—
denominator unverified
|
—
35,000 shares
|
— | 29 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
2,009,303
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
3
Q1 2024 holders
3
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend